European Review for Medical and Pharmacological Sciences-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2023-06-02 ms7000000507856696 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：综合性期刊
经验分享：这个杂志的发表有办法的，能保证录用。

50 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2023-05-14 ms7000000507856696 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：临床药理;肿瘤;综合性期刊
经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发

36 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2023-05-23 ms1000001665216280 来自吉林省

偏重的研究方向：生信
经验分享：请问网络药理学没有实验验证的论文能接收吗

1 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2023-01-25 ms7000001910214771 来自辽宁省

要提交原始数据嘛

40 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2023-04-14 Daisy大林木来自山东省

为什么杂志官网能查到但是pubmed上搜不到呢

30 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2023-02-02 Daisy大林木来自山东省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢

40 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2019-08-11 perfectime

请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表::
我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表:
我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？

zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？

92 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2020-04-26 1247f785m03(暂无昵称)

是的我09 2020-04-25 00:00:00 发表:
一直是under consideration吗

我09 2020-04-25 00:00:00 发表: 一直是under consideration吗

76 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2020-07-21 WHNY

我才投，under consideration中，需要马上撤稿吗？

172 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2140485, encodeId=4b0721404851b, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：综合性期刊 经验分享：这个杂志的发表有办法的，能保证录用。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Fri Jun 02 15:16:44 CST 2023, time=2023-06-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2133755, encodeId=6d7d2133e5545, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：临床药理;肿瘤;综合性期刊 经验分享：这个杂志的发表还是有窍门的，本人发表了8篇，可以说是随便发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Sun May 14 16:44:35 CST 2023, time=2023-05-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2138499, encodeId=6609213849977, content=偏重的研究方向：生信 经验分享：请问网络药理学没有实验验证的论文能接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2f8354310, createdName=ms1000001665216280, createdTime=Tue May 23 02:55:44 CST 2023, time=2023-05-23, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2111379, encodeId=03b221113e9d6, content=要提交原始数据嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e495467216, createdName=ms7000001910214771, createdTime=Wed Jan 25 08:40:41 CST 2023, time=2023-01-25, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2125887, encodeId=1ad0212588e97, content=为什么杂志官网能查到但是pubmed上搜不到呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Fri Apr 14 13:31:03 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2112692, encodeId=b0872112692ff, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：为什么接收5个月了还没发表啊？这个杂志是有多慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QbttTiaiaGsyj0xJM11oKBl4lt5Hx9tgehd6oRWQ1dGibULlCSp3hvBiccQnT0NyR2aJxw/132, createdBy=063c108027, createdName=Daisy大林木, createdTime=Thu Feb 02 09:00:35 CST 2023, time=2023-02-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=574670, encodeId=a8de5e467033, content=请问这个杂志好投吗要原始数据吗zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？zysciif 2019-07-18 00:00:00 发表: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, beContent=zysciif 2019-07-18 发表:: 我这边支付版面费，两天就Proof，你是不是付款了，没有给杂志社发邮件啊？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=048c2180411, createdName=perfectime, createdTime=Sun Aug 11 00:00:00 CST 2019, time=2019-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589732, encodeId=c6b7589e32de, content=是的我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , beContent=我09 2020-04-25 00:00:00 发表: 一直是under consideration吗 , objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0e2492369, createdName=1247f785m03(暂无昵称), createdTime=Sun Apr 26 00:00:00 CST 2020, time=2020-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803772, encodeId=e41e803e726d, content=我才投，under consideration中，需要马上撤稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2fdc99717, createdName=WHNY, createdTime=Tue Jul 21 23:08:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096292, encodeId=90cc209629218, content=一个月了还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0f5698970, createdName=ms9000000591668568, createdTime=Wed Oct 26 16:43:17 CST 2022, time=2022-10-26, status=1, ipAttribution=)]

2022-10-26 ms9000000591668568

一个月了还在under consideration

35 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务